SBM.V - Sirona Biochem Corp.

TSXV - TSXV Real Time Price. Currency in CAD
0.1400
0.0000 (0.00%)
At close: 03:32PM EDT
Stock chart is not supported by your current browser
Previous Close0.1400
Open0.1400
Bid0.1300 x 0
Ask0.1550 x 0
Day's Range0.1400 - 0.1600
52 Week Range0.0800 - 0.3500
Volume70,000
Avg. Volume86,461
Market Cap35.296M
Beta (5Y Monthly)-0.30
PE Ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings DateMar 29, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 27, 2006
1y Target EstN/A
  • GlobeNewswire

    Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives

    VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to announce it has contracted Atheln Inc. ("Atheln"), a leading US consulting firm, to bolster and facilitate Sirona's business activities. This strategic initiative comes at an opportune time, as Sirona prepares for the highly anticipated BIO International 2023 conference in Boston, where it will showcase its groundbreaking anti-aging compound, TFC-1326.

  • GlobeNewswire

    Sirona Biochem: Investing News Network Interview with CSO, Dr. Geraldine Deliencourt-Godefroy

    An In-Depth Look at Anti-Aging Compound TFC-1326VANCOUVER, British Columbia, May 11, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that the Investing News Network has published an exclusive video interview with Dr. Geraldine Deliencourt-Godefroy, the Chief Scientific Officer of Sirona. In the interview, Dr. Deliencourt-Godefroy shares the remarkable story behind her groundbreaking discovery in anti-aging, TFC-1326, and dis

  • GlobeNewswire

    Sirona Biochem to Present Ground-breaking Anti-Aging Technology at BIO 2023 Conference in Boston

    VANCOUVER, British Columbia, May 03, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTCQB: SRBCF) ("Sirona") is excited to announce that Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer, will be presenting the Company's latest anti-aging technology, TFC-1326, at the upcoming BIO International 2023 conference in Boston. The conference, which is the largest in the industry, will take place from June 5-8, 2023. TFC-1326 is a revolutionary anti-aging compound that

  • GlobeNewswire

    Sirona Biochem Announces Exceptional Clinical Trial Results for Anti-Aging Compound TFC-1326

    BEFORE Unretouched photos, taken in standard lighting. Results may vary. AFTER Unretouched photos, taken in standard lighting. Results may vary. BEFORE Unretouched photos, taken in standard lighting. Results may vary. AFTER Unretouched photos, taken in standard lighting. Results may vary. VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical trial results, for novel anti-aging

  • GlobeNewswire

    Sirona Biochem Announces Close of Oversubscribed Debenture Financing

    VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (Xetra: ZSB) (the “Company”) announced today that it has closed an oversubscribed, non-brokered convertible debenture for gross proceeds of $1,563,600. The private placement consists of 1,563 Debenture units, (the “Debenture Units”) at a price of $1,000 per Debenture Unit. Dr. Howard Verrico, CEO, subscribed to $500,000 of Debenture Units. Dr. Verrico’s participation is a “related p

  • GlobeNewswire

    Sirona Biochem Announces Debenture Financing

    VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “Convertible Debentures”). The Company is offering Convertible Debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $1,500,000 (the “Offering”). Each Debenture Unit will have a

  • Simply Wall St.

    Sirona Biochem Full Year 2022 Earnings: CA$0.015 loss per share (vs CA$0.01 loss in FY 2021)

    Sirona Biochem ( CVE:SBM ) Full Year 2022 Results Key Financial Results Revenue: CA$671.9k (up 151% from FY 2021). Net...

  • GlobeNewswire

    Sirona Biochem Receives Antiviral Testing Results

    VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has received results from its research collaboration with the International Centre for Genetic Engineering and Biotechnology (“ICGEB”) to advance Sirona’s antiviral library of compounds. The ICGEB has successfully screened a library of 20 compounds produced at Sirona’s subsidiary TFChem as potential inhibitors of SARS-CoV-2 using specialize

  • GlobeNewswire

    Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields

    VANCOUVER, British Columbia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the termination of the Rodan + Fields (R+F) agreement for supply and use of TFC-1067 in commercial formulations. Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will now be the sole licensee of the technology as per the agreement signed June 2022. About Sirona Biochem Corp.Sirona Biochem is a cosmetic ingredient and drug discovery company with a propr

  • GlobeNewswire

    Sirona Biochem Announces 2022 Annual Meeting Results

    VANCOUVER, British Columbia, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on December 30, 2022. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 23,664,112, representing 9.39% of Sirona's issued and outstanding Common Shares. All matters put forward to sha

  • GlobeNewswire

    Sirona Biochem Announces Start of Clinical Trial for Anti-Aging Compound TFC-1326

    VANCOUVER, British Columbia, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical trial, for novel anti-aging compound TFC-1326, started on December 5th, 2022. The trial, which will take place in Paris, is designed to assess the compound’s efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine wrinkles. The formulation is a cream base with TFC-1326 at a concen

  • GlobeNewswire

    Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals

    VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals (“Wanbang”) have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunitie

  • GlobeNewswire

    Sirona Biochem Reports Positive Results in Safety Study for Anti-Aging Compound TFC-1326

    VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce positive results of the clinical safety study for their novel anti-aging compound TFC-1326 1% in formulation, now proven to be a non-irritant and non-sensitizer. TFC-1326, Sirona’s lead anti-aging compound, will soon enter a clinical trial designed to assess its potential to reverse the effects of aging on facial skin, restoring lost volume an

  • GlobeNewswire

    Sirona Biochem Signs Research Collaboration Agreement with International Centre for Genetic Engineering and Biotechnology

    VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has entered into a research collaboration with the International Centre for Genetic Engineering and Biotechnology (“ICGEB”) to advance Sirona’s antiviral library of compounds. ICGEB will immediately begin screening the library of compounds produced at Sirona’s subsidiary TFChem. The work will be performed at the ICGEB’s Laboratory of Molecu

  • GlobeNewswire

    Sirona Biochem Issues Corporate Update

    VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) announces the release of a corporate update which highlights the company’s recent team meeting in France, the current pipeline, and the latest deal structure. With the success of the licensing deal with AbbVie, the company needs to prepare for its next phase of growth. Dr. Wolfgang Bieber reports “In my professional opinion, as a chemist of over three decades, I

  • GlobeNewswire

    Sirona Biochem Corporate Update

    VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased to provide an outlook of our ongoing corporate development. On June 13th we announced that we had successfully completed an exclusive global license for TFC-1067 and related family of compounds with Allergan Aesthetics (an AbbVie company). This deal represents a major milestone for Sirona and one we ha

  • GlobeNewswire

    Sirona Biochem Contracts WuXi AppTec to Manufacture Revolutionary Anti-Aging/Anti-Wrinkle Compound for Clinical Trial

    VANCOUVER, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that it has signed an agreement with Contract Manufacturing Organization (CMO) WuXi AppTec (“WuXi”), Shanghai, for the small-scale production of TFC-1326, a powerful active against the aging effects on skin. Years of groundbreaking research by Sirona’s team of scientists at TFChem has shown in preclinical studies that TFC-1326 has the potentia

  • Baystreet

    Sirona Hits 52-week High on New Promotion

    Sirona Biochem Corp. (V.SBM) hit a new 52-week high of 31 cents. Sirona announced that Dr. Wolfgang ...

  • GlobeNewswire

    Former Bayer Senior Executive Joins Sirona Biochem Advisory Board

    VANCOUVER, British Columbia, June 20, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that Dr. Wolfgang Bieber will join Sirona Biochem’s Advisory Board and act as a consultant to the Board of Directors with immediate effect. Dr. Wolfgang Bieber brings to Sirona Biochem 30 years of experience from his career at BAYER AG, a global pharmaceutical and agrochemical company with sales of US$52 billion and more than 100,000 employees

  • GlobeNewswire

    Sirona Biochem Initiates Significant Corporate Changes

    VANCOUVER, British Columbia, June 15, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to inform about several significant corporate changes currently in preparation: Now that Sirona Biochem has closed an exclusive global licencing agreement with Allergan Aesthetics, the next steps for sustainable and rapid growth of the company are initiated. The Board has begun a strategic review of every facet of the company including management, organiz

  • GlobeNewswire

    Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

    Licenses Revolutionary Skin Care Compound TFC-1067VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-106